U.S. markets closed
  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     
  • Dow 30

    33,507.50
    -158.84 (-0.47%)
     
  • Nasdaq

    13,219.32
    +18.05 (+0.14%)
     
  • Russell 2000

    1,785.10
    -9.21 (-0.51%)
     
  • Crude Oil

    90.77
    -0.94 (-1.02%)
     
  • Gold

    1,864.60
    -14.00 (-0.75%)
     
  • Silver

    22.39
    -0.35 (-1.54%)
     
  • EUR/USD

    1.0575
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    4.5730
    -0.0240 (-0.52%)
     
  • GBP/USD

    1.2201
    -0.0005 (-0.04%)
     
  • USD/JPY

    149.3300
    +0.0560 (+0.04%)
     
  • Bitcoin USD

    27,188.08
    +210.61 (+0.78%)
     
  • CMC Crypto 200

    579.66
    +0.90 (+0.15%)
     
  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     
  • Nikkei 225

    31,857.62
    -14.90 (-0.05%)
     

Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc.

BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2022 at 4:20 PM ET.

A live webcast of the presentation will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 30 days.

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843